Published in Clin Cancer Res on July 01, 2002
Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem (2009) 1.67
Triclocarban enhances testosterone action: a new type of endocrine disruptor? Endocrinology (2007) 1.63
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol (2012) 1.01
Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins. J Cell Physiol (2012) 0.93
Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochim Biophys Acta (2007) 0.93
Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer (2011) 0.91
Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog (2009) 0.80
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 3.01
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol (2004) 2.27
A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology (2008) 2.03
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol (2009) 1.80
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res (2011) 1.75
Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. J Med Chem (2006) 1.71
Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol (2012) 1.68
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci U S A (2009) 1.61
Ethnic-specific differences in bronchodilator responsiveness among African Americans, Puerto Ricans, and Mexicans with asthma. J Asthma (2007) 1.57
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol (2003) 1.57
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell (2004) 1.57
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res (2013) 1.46
Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet (2006) 1.43
A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab (2010) 1.42
A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem (2006) 1.38
Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem (2008) 1.38
Human pancreatic precursor cells secrete FGF2 to stimulate clustering into hormone-expressing islet-like cell aggregates. Proc Natl Acad Sci U S A (2003) 1.38
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci (2009) 1.37
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res (2012) 1.35
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell (2004) 1.28
Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem (2007) 1.28
Admixture-matched case-control study: a practical approach for genetic association studies in admixed populations. Hum Genet (2005) 1.27
Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J Med Chem (2007) 1.26
Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J Biomol Screen (2008) 1.25
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol (2003) 1.24
Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. Ann Allergy Asthma Immunol (2008) 1.23
A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. J Am Chem Soc (2008) 1.20
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology (2010) 1.20
Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells (2007) 1.20
Endocrine precursor cells from mouse islets are not generated by epithelial-to-mesenchymal transition of mature beta cells. Mol Cell Endocrinol (2007) 1.19
Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol (2006) 1.19
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res (2004) 1.16
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med (2005) 1.14
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer (2002) 1.14
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med (2007) 1.12
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med (2005) 1.10
Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta (2004) 1.10
The human insulin gene displays transcriptionally active epigenetic marks in islet-derived mesenchymal precursor cells in the absence of insulin expression. Stem Cells (2007) 1.09
Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem (2008) 1.09
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res (2005) 1.08
Case of renal myxoma. Int J Urol (2007) 1.08
Impact of surgeon and surgical center characteristics on choice of permanent vascular access. Kidney Int (2003) 1.05
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem (2004) 1.04
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res (2005) 1.04
[Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]. Hinyokika Kiyo (2010) 1.04
Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol (2008) 1.03
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate (2008) 1.02
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm (2016) 1.02
Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. J Allergy Clin Immunol (2007) 1.02
Engaging communities in education and research: PBRNs, AHEC, and CTSA. Clin Transl Sci (2012) 1.02
Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol (2011) 1.01
Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem (2008) 1.01
A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid (2012) 1.00
Atomistic insights into rhodopsin activation from a dynamic model. J Am Chem Soc (2008) 1.00
Low affinity analogs of thyrotropin-releasing hormone are super-agonists. J Biol Chem (2006) 1.00
Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res (2003) 1.00
Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol (2006) 0.99
[A case of leiomyosarcoma in a huge bladder diverticulum]. Hinyokika Kiyo (2009) 0.99
Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on internalization. FASEB J (2010) 0.99
The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene (2002) 0.98
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res (2004) 0.97
Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol (2009) 0.96
Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev (2005) 0.95
Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol (2004) 0.95
Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor. FASEB J (2010) 0.94
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer (2013) 0.94
A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab (2013) 0.93
Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochim Biophys Acta (2007) 0.93
Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling. Mol Pharmacol (2011) 0.93
TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes. Neuropsychopharmacology (2008) 0.93
Trypsin and thrombin accelerate aggregation of human endocrine pancreas precursor cells. J Cell Physiol (2006) 0.93
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer (2006) 0.93
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res (2002) 0.93
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int (2011) 0.92